Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Gastrointestinal Adverse Events Across The Rheumatoid Arthritis Clinical Program

被引：0
|
作者：
Lee, E. B. [1 ]
Curtis, J. R. [2 ]
Riese, R. [3 ]
Connell, C. A. [3 ]
Chew, R. [3 ]
Boy, M. G. [3 ]
Maller, E. [4 ]
Su, C. [4 ]
Wang, L. [3 ]
机构：
[1] Seoul Natl Univ, Seoul, South Korea
[2] Univ Alabama Birmingham, Birmingham, AL USA
[3] Pfizer Inc, Groton, CT 06340 USA
[4] Pfizer Inc, Collegeville, PA USA
来源：
ARTHRITIS AND RHEUMATISM | 2013年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
439
引用
收藏
页码：S191 / S191
页数：1
相关论文
共 50 条
  • [1] Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Malignancies Across The Rheumatoid Arthritis Clinical Program
    Mariette, X.
    Curtis, J. R.
    Lee, E. B.
    Benda, B.
    Kaplan, I.
    Soma, K.
    Chew, R.
    Geier, J.
    Wang, L.
    Riese, R.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S340 - S340
  • [2] TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR: ANALYSIS OF GASTROINTESTINAL ADVERSE EVENTS ACROSS THE RHEUMATOID ARTHRITIS CLINICAL PROGRAMME
    Lee, E. B.
    Curtis, J. R.
    Riese, R.
    Connell, C.
    Chew, R.
    Boy, M.
    Maller, E.
    Su, C.
    Wang, L.
    Bradley, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 202 - 203
  • [3] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: ANALYSIS OF MALIGNANCIES ACROSS THE RHEUMATOID ARTHRITIS CLINICAL PROGRAMME
    Mariette, X.
    Curtis, J.
    Lee, E.
    Benda, B.
    Kaplan, I.
    Soma, K.
    Kwok, K.
    Geier, J.
    Wang, L.
    Riese, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 230 - 230
  • [4] Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
    Curtis, Jeffrey R.
    Lee, Eun Bong
    Kaplan, Irina V.
    Kwok, Kenneth
    Geier, Jamie
    Benda, Birgitta
    Soma, Koshika
    Wang, Lisy
    Riese, Richard
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (05) : 831 - 841
  • [5] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: ANALYSIS OF MALIGNANCIES IN JAPANESE PATIENTS ACROSS THE RHEUMATOID ARTHRITIS CLINICAL PROGRAMME
    Tanaka, Y.
    Takeuchi, T.
    Yamanaka, H.
    Hirose, T.
    Toyoizumi, S.
    Zwillich, S.
    Geier, J.
    Riese, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 230 - 231
  • [6] Tofacitinib: A novel oral Janus kinase inhibitor for rheumatoid arthritis
    O'Dell, Kate M.
    Rummel, Ashley E.
    FORMULARY, 2012, 47 (10) : 350 - +
  • [7] TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR: ANALYSIS OF MALIGNANCIES ACROSS THE RHEUMATOID ARTHRITIS CLINICAL PROGRAMME
    Marlette, X.
    Curtis, J. R.
    Lee, E. B.
    Riese, R.
    Kaplan, I.
    Chew, R.
    Geier, J.
    Wang, L.
    Bradley, J. D.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 199 - 199
  • [8] Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis
    Dowty, Martin E.
    Jesson, Michael I.
    Ghosh, Sarbani
    Lee, Jamie
    Meyer, Debra M.
    Krishnaswami, Sriram
    Kishore, Nandini
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2014, 348 (01): : 165 - 173
  • [9] Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program
    Lichtenstein, Gary R.
    Rogler, Gerhard
    Ciorba, Matthew A.
    Su, Chinyu
    Chan, Gary
    Pedersen, Ronald D.
    Lawendy, Nervin
    Quirk, Daniel
    Nduaka, Chudy, I
    Thorpe, Andrew J.
    Panes, Julian
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (06) : 816 - 825
  • [10] The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis
    Hodge, J. A.
    Kawabata, T. T.
    Krishnaswami, S.
    Clark, J. D.
    Telliez, J. -B.
    Dowty, M. E.
    Menon, S.
    Lamba, M.
    Zwillich, S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (02) : 318 - 328
12345